Skip to main content

Biogen Inc.

BIIB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000875045

In the last 90 days, Biogen Inc. insiders filed 0 open-market purchases and 1 sale; 1,046 institutions reported holding it in 13F filings for Q2 2026, worth $30.7B in total; no superinvestor holds it.

Holders of 5% or more of BIIB

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Biogen Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of BIIB
HolderLatest formStakeChangeFirst filedLatest filingFiling
Primecap Management Co13G/A10.20%15.0M shares–Nov 13, 20251 filingNov 13, 2025SEC
BlackRock, Inc.13G/A8.50%12.5M shares–Apr 17, 20251 filingApr 17, 2025SEC
State Street Corp13G5.00%7.32M sharesNewNov 10, 20251 filingNov 10, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

4 Schedule 13D and 13G filings on Biogen Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on BIIB
Filed (ET)FilerFormStakeChangeEvent dateFiling
Mar 26, 20264:09 PM ETVanguard Group Inc13G/A0.00%0 shares–Below 5%Mar 13, 2026SEC
Nov 13, 20258:28 PM ETPrimecap Management Co13G/A10.20%15.0M shares–Sep 30, 2025SEC
Nov 10, 20258:15 AM ETState Street Corp13G5.00%7.32M sharesNewSep 30, 2025SEC
Apr 17, 20259:35 AM ETBlackRock, Inc.13G/A8.50%12.5M shares–Mar 31, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Biogen Inc. shares.

No Form 144 notices for Biogen Inc. are on file.